ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Instil Bio, Inc. (TIL) stock surged +3.53%, trading at $16.00 on NASDAQ, up from the previous close of $15.46. The stock opened at $15.43, fluctuating between $15.20 and $16.23 in the recent session.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Employees | 14 |
Beta | 1.76 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |